Clinical Research Directory
Browse clinical research sites, groups, and studies.
Liver X Receptor (LXR) as a Novel Therapeutic Target in Diabetic Retinopathy (DR)
Sponsor: University of Alabama at Birmingham
Summary
Results from large clinical trials demonstrate a strong association between lipid abnormalities and progression of the most common microvascular complication, diabetic retinopathy (DR). We found that activation of a master regulator of cholesterol metabolism, the nuclear hormone receptors liver X receptors (LXRα/LXRβ), prevents DR in rodent models. In this application, we seek to understand the mechanisms responsible for the beneficial effects of LXR agonists on retina and on bone marrow (BM) to preserve the function of reparative cells while reducing inflammatory cell.
Official title: LXR as a Novel Therapeutic Target in DR
Key Details
Gender
All
Age Range
21 Years - 98 Years
Study Type
OBSERVATIONAL
Enrollment
104
Start Date
2018-01-11
Completion Date
2026-12-31
Last Updated
2025-09-17
Healthy Volunteers
Yes
Conditions
Interventions
blood draw
Blood sample will be obtained and CD34+ cells will be isolated for functional testing.
Locations (1)
University of Alabama at Birmingham
Birmingham, Alabama, United States